We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PwC Report Highlights Skepticism Among Drugmakers Over User Fees
PwC Report Highlights Skepticism Among Drugmakers Over User Fees
February 24, 2011
As the FDA continues its push to develop a user fee program for generic-drug makers, a survey is highlighting drugmakers’ skepticism about the probable effectiveness of such fees and reinforcing calls for more frequent communication with the agency.